葛兰素史克多发性骨髓瘤联合疗法试验中期分析获积极结果

智通财经03-07

3月7日，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤(RRMM)联合疗法的试验中期分析取得积极结果。这项名为DREAMM-8的试验评估了Blenrep (belantamab mafodotin)联合泊马度胺加地塞米松(PomDex)与标准治疗硼替佐米联合PomDex的疗效。一项预先指定的中期分析显示，该试验达到了无进展生存期的主要终点，与标准治疗组合相比，belantamab ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2417768033?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2024-03-07 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2417768033","market":"us","top_or_hot":-1,"title":"葛兰素史克多发性骨髓瘤联合疗法试验中期分析获积极结果","media":"智通财经","content":"<div>\n<p>3月7日，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤(RRMM)联合疗法的试验中期分析取得积极结果。这项名为DREAMM-8的试验评估了Blenrep (belantamab mafodotin)联合泊马度胺加地塞米松(PomDex)与标准治疗硼替佐米联合PomDex的疗效。一项预先指定的中期分析显示，该试验达到了无进展生存期的主要终点，与标准治疗组合相比，belantamab ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1083139.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰素史克多发性骨髓瘤联合疗法试验中期分析获积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰素史克多发性骨髓瘤联合疗法试验中期分析获积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-07 21:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1083139.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月7日，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤(RRMM)联合疗法的试验中期分析取得积极结果。这项名为DREAMM-8的试验评估了Blenrep (belantamab mafodotin)联合泊马度胺加地塞米松(PomDex)与标准治疗硼替佐米联合PomDex的疗效。一项预先指定的中期分析显示，该试验达到了无进展生存期的主要终点，与标准治疗组合相比，belantamab ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1083139.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1083139.html","article_id":"2417768033","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2417768033","pubTimestamp":1709816494,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤联合疗法的试验中期分析取得积极结果。中期分析还观察到有利于Blenrep组合的积极总生存期趋势。此外，该联合疗法的安全性和耐受性与已知的单个药物的安全性大致一致。葛兰素史克早些时候公布了DREAMM-7试验的积极结果。截至发稿，葛兰素史克盘前涨2.63%，报43.74美元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","BK4585":"ETF&股票定投概念"},"translate_title":"Mid-term analysis of GlaxoSmithKline multiple myeloma combination therapy trial achieved positive results","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/7f37b43d7f6a4878e4026a04135a6e35","symbols_score_info":{"GSK":1},"content_text":"3月7日，葛兰素史克周四公布了一项评估复发或难治性多发性骨髓瘤(RRMM)联合疗法的试验中期分析取得积极结果。这项名为DREAMM-8的试验评估了Blenrep (belantamab mafodotin)联合泊马度胺加地塞米松(PomDex)与标准治疗硼替佐米联合PomDex的疗效。一项预先指定的中期分析显示，该试验达到了无进展生存期的主要终点，与标准治疗组合相比，belantamab mafodotin组合显著延长了疾病进展或死亡的时间。中期分析还观察到有利于Blenrep组合的积极总生存期趋势。此外，该联合疗法的安全性和耐受性与已知的单个药物的安全性大致一致。葛兰素史克早些时候公布了DREAMM-7试验的积极结果。DREAMM-7试验评估了belantamab mafodotin 联合硼替佐米和地塞米松 (BorDex)与达雷妥尤单抗联合 BorDex 在相同治疗环境中的疗效。葛兰素史克表示：“DREAMM-7和DREAMM-8的研究结果提供了强有力的临床证据，证明belantamab mafodotin与标准治疗组合使用具有强大的疗效。我们现在期待着与监管机构讨论这些数据。”截至发稿，葛兰素史克盘前涨2.63%，报43.74美元。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2417768033"}